GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Cerus Corporation
Cerus Corporation has developed a technology for inactivating pathogens in donor blood components. Its stock price reflects the adoption of this technology in blood centers worldwide, improving the safety of blood transfusions.
Share prices of companies in the market segment - Medical instruments
Cerus Corporation develops technologies to improve the safety of donor blood and platelets by inactivating pathogens. We've categorized it as "Medical Instruments." The chart below shows how the market values companies operating in the critical area of blood component safety.
Broad Market Index - GURU.Markets
Cerus Corporation develops technologies to improve the safety of donor blood and platelets by inactivating pathogens. We've classified it under "Medical Instruments." The chart below shows how the market values companies operating in the critical area of blood component safety.
Change in the price of a company, segment, and market as a whole per day
CERS - Daily change in the company's share price Cerus Corporation
For Cerus, a blood safety specialist, change_co is a measure of volatility in the medtech sector. Daily fluctuations reflect sensitivity to blood bank contracts and regulatory news. This metric is important for analyzing niche medical companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Medical instruments
Cerus Corporation is a company in the blood safety sector. This chart shows average daily volatility. Comparing it to CERS, with its unique technology, helps assess how dependent its business is on contracts with blood banks.
Daily change in the price of a broad market stock, index - GURU.Markets
Cerus is a manufacturer of blood donation safety systems. Its business is an integral part of the healthcare sector. The chart below illustrates the overall market volatility, which may make Cerus appear more stable.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Cerus Corporation
Cerus Corporation's year-over-year performance is a story about the safety of donor blood. Its market capitalization growth over the past 12 months reflects the growing number of blood banks using its INTERCEPT system for inactivating pathogens in platelets and plasma, which is becoming the global standard for reducing the risk of transfusion-related infections.
Annual dynamics of market capitalization of the market segment - Medical instruments
Cerus Corporation is a leader in technologies to ensure the safety of blood components such as plasma and platelets. Its systems are used to inactivate pathogens. The chart shows how its dominant position in this critical niche and the growing adoption of its technologies are driving its steady growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cerus, with its blood component safety technology, operates in the protective sector. Demand for its products is driven by healthcare standards, not economics. The company's share price reflects its success in commercialization and innovation, making it a non-cyclical growth story.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Cerus Corporation
The value of Cerus, a blood safety company, depends on the adoption of its technology. The monthly fluctuations in the chart reflect the growth of sales of its INTERCEPT system for inactivating pathogens in blood components, a key indicator of its operational growth.
Monthly dynamics of market capitalization of the market segment - Medical instruments
Cerus Corporation developed INTERCEPT technology to improve the safety of donated blood by neutralizing pathogens such as viruses and bacteria. The graph below shows the overall trend in the medical device sector, where the safety of blood components is a critical issue.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cerus Corporation develops technologies to improve the safety of donor blood. Demand for its products is stable and growing as safety standards improve. This gives the company's shares a defensive nature, and their performance is often less volatile and weakly correlated with overall market fluctuations.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Cerus Corporation
Shares of Cerus Corporation, whose technology improves the safety of donor blood, reflect trends in healthcare. Weekly price movements depend on news about the implementation of their system in blood banks worldwide and regulatory decisions. The chart below shows how short-term developments in this sector influence the company's valuation.
Weekly dynamics of market capitalization of the market segment - Medical instruments
How does Cerus Corporation's performance compare to the medical equipment sector? The chart below compares the blood safety company's weekly stock price movements with the industry average. This helps us understand whether its reaction to the news of its system's implementation in blood banks is typical, or whether its niche specialization is creating a unique trajectory.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Cerus Corporation supplies systems to improve the safety of donor blood. This chart compares its weekly performance to the market. It helps understand whether its business, which involves vital medical procedures, provides price stability and protection from general economic downturns.
Market capitalization of the company, segment and market as a whole
CERS - Market capitalization of the company Cerus Corporation
Cerus Corporation's valuation on the chart is a bet on its INTERCEPT technology to improve donor blood safety. The company's market capitalization depends on the implementation of its pathogen-inactivating system in blood banks worldwide. The dynamics show how investors assess its potential to become a global standard.
CERS - Share of the company's market capitalization Cerus Corporation within the market segment - Medical instruments
Cerus Corporation dominates the market for pathogen inactivation of blood components, capturing a huge share with its Intercept system. Its market capitalization reflects its near-monopoly position in improving blood transfusion safety.
Market capitalization of the market segment - Medical instruments
The chart below is a barometer of the blood product safety technology market. Cerus Corporation, with its Intercept system, is the global standard. The dynamics in the chart demonstrate how stable and important this market is for healthcare systems worldwide.
Market capitalization of all companies included in a broad market index - GURU.Markets
This graph depicts the market value of blood safety. The market capitalization of Cerus Corporation, whose technology inactivates pathogens in donor blood, reflects the global need for infection protection. The line shows the importance of technology that makes blood transfusions safer in the global healthcare system.
Book value capitalization of the company, segment and market as a whole
CERS - Book value capitalization of the company Cerus Corporation
This is an assessment of Cerus Corporation's inventory. The chart reflects the value of its production capacity and, more importantly, the patents for the INTERCEPT system for inactivating pathogens in donor blood and platelets. The growth of this line indicates investment in technology that improves blood transfusion safety.
CERS - Share of the company's book capitalization Cerus Corporation within the market segment - Medical instruments
Cerus Corporation's physical infrastructure consists of production lines for its INTERCEPT systems, which are used to improve blood donation safety. The chart shows the company's share of this critical healthcare manufacturing infrastructure, which protects patients worldwide.
Market segment balance sheet capitalization - Medical instruments
Below you can see the overall book value of the medical equipment sector. Against this backdrop, Cerus, with its blood product safety technology, is capital-intensive. The production of its systems and consumables requires certified and sophisticated manufacturing facilities.
Book value of all companies included in the broad market index - GURU.Markets
Cerus Corporation produces the Intercept system, which improves the safety of donor blood. The company's assets are factories that produce consumables for this system. Their balance sheet represents the value of the technology that protects the healthcare system's "circulatory system." This is an important, albeit invisible, part of real-world medicine.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Cerus Corporation
Cerus's balance sheet is the value of its factories. Its market capitalization is a measure of its near-monopoly position in the blood purification systems market. The MvsBCap_Co chart, when it's above one, shows the premium the market pays for a technology that has become a safety standard in medicine.
Market to book capitalization ratio in a market segment - Medical instruments
Cerus Corporation has developed a technology to improve the safety of donor blood by inactivating pathogens. The chart shows how the market values its unique technology and its potential to become a global standard in blood transfusion, which translates into a premium for its manufacturing assets.
Market to book capitalization ratio for the market as a whole
Cerus Corporation developed INTERCEPT technology to improve the safety of transfused blood by inactivating pathogens. The company's value lies in its unique and approved technology. This chart helps explain why the medical technology sector often trades at a premium to its book value, reflecting a belief in innovation and safety.
Debts of the company, segment and market as a whole
CERS - Company debts Cerus Corporation
For Cerus Corporation, a blood safety company, debt is a tool for the global adoption of its technology. This chart shows how the company is raising capital to promote its system for inactivating pathogens in blood components worldwide. Debt is helping set a new standard for safety in blood banks and hospitals.
Market segment debts - Medical instruments
Cerus Corporation developed INTERCEPT technology to improve the safety of donor blood and platelets by inactivating pathogens. Implementing new standards in medicine is a long process. This chart shows how the company is funding the commercialization of its life-saving technology and how its financial structure reflects its unique market position.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Cerus Corporation
Cerus Corporation specializes in blood product safety technologies. This chart shows how the company finances its operations. For a company in the medical technology niche, where product introduction takes time and regulatory approval, debt levels are an important indicator of financial flexibility and the ability to survive long sales cycles.
Market segment debt to market segment book capitalization - Medical instruments
Cerus Corporation has developed a technology for inactivating pathogens in blood components, improving transfusion safety. Commercializing this system requires investment. The chart shows how the company's debt burden compares to overall market capitalization and financial standards in the medical technology sector.
Debt to book value of all companies in the market
Cerus Corporation (CERS) supplies technologies to improve blood transfusion safety. This is an important niche in healthcare with stable demand. This chart reflects the overall debt-to-equity ratio in the market. It helps understand how a medical technology company with a mature product manages its debt load for future growth.
P/E of the company, segment and market as a whole
P/E - Cerus Corporation
For Cerus Corporation, a company whose technology improves the safety of donor blood, this chart reflects the implementation of its standard in blood banks. The P/E ratio is driven by sales of consumables for its system. The growth is driven by the expanding use of its technology worldwide for pathogen protection.
P/E of the market segment - Medical instruments
This chart illustrates the average P/E for medical instrument manufacturers. For Cerus, with its blood safety technology, this is an important benchmark. Comparing its P/E to the industry average helps understand how investors view its unique niche and the potential for its technology to become a global standard.
P/E of the market as a whole
Cerus Corporation develops and markets the INTERCEPT system to improve the safety of transfused blood. The company's technology inactivates pathogens (viruses and bacteria) in platelets and plasma, reducing risks to patients. This chart, reflecting overall sentiment, helps understand how investors value companies setting safety standards in medicine.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Cerus Corporation
Cerus Corporation developed INTERCEPT technology to improve donor blood safety by inactivating pathogens (viruses and bacteria). This graph shows the expected impact of implementing higher blood safety standards. This assessment depends on the adoption of its technology by blood centers worldwide and increased sales of consumables for its system.
%20P%2FE%20Cerus%20Corporation&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Cerus-Corporation&v=1772513775971 "Chart of the company's future (projected) P/E Cerus Corporation")
Future (projected) P/E of the market segment - Medical instruments
Cerus Corporation specializes in blood safety technologies, offering the INTERCEPT system for inactivating pathogens in blood components. This chart compares the company's future profitability expectations with the industry average. It reflects the market's confidence that their technology will become the global standard for blood banks.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Medical%20instruments&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Medical-instruments&v=1772513775983 "Future (projected) P/E graph of the market segment - Medical instruments")
Future (projected) P/E of the market as a whole
Cerus Corporation has developed a technology for inactivating pathogens in donor blood and platelets, improving transfusion safety. Its business depends on the implementation of this technology in blood banks. This market outlook is less important to Cerus than the decisions of regulators and healthcare systems around the world.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513775985 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Cerus Corporation
Cerus Corporation developed INTERCEPT technology to improve the safety of donor blood. This system inactivates pathogens (viruses and bacteria) in blood components before transfusion. The company's profits depend on the implementation of its technology in blood banks worldwide.
Profit of companies in the market segment - Medical instruments
Cerus Corporation has developed a technology for inactivating pathogens in donor blood, improving transfusion safety. Demand for the Intercept system depends on regulatory requirements and hospital adoption. This chart illustrates how companies raising safety standards in medicine are creating a new, steadily growing niche, impacting overall sector profitability.
Overall market profit
Cerus Corporation has developed technology to improve the safety of donor blood. Demand for its Intercept systems is driven by medical safety standards and the need to protect against pathogens. This makes the company's business non-cyclical and dependent on the decisions of regulators and blood banks, rather than the state of the economy, as shown in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Cerus Corporation
Cerus Corporation developed INTERCEPT technology to improve donor blood safety by inactivating pathogens. This chart shows revenue expectations based on the adoption of this technology by blood centers worldwide. Regulatory requirements and awareness of the risks of blood transfusion are key drivers of demand.
%20profit%20of%20the%20company%20Cerus%20Corporation&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Cerus-Corporation&v=1772513776118 "Graph of future (projected) profit of the company Cerus Corporation")
Future (predicted) profit of companies in the market segment - Medical instruments
Cerus Corporation developed the INTERCEPT system to improve donor blood safety by inactivating pathogens. This graph shows the revenue forecast for the medical devices sector. It reflects expectations for the implementation of new blood safety standards worldwide. This trend is the main driver for the expansion of Cerus' technology.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Medical%20instruments&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Medical-instruments&v=1772513776148 "Graph of future (predicted) profits of companies in a market segment - Medical instruments")
Future (predicted) profit of the market as a whole
Cerus Corporation produces systems to improve the safety of donor blood. Demand for its products depends on blood transfusion standards and blood bank budgets. Economic growth, as projected in the graph, ensures stable funding for healthcare systems, allowing them to implement advanced safety technologies like those offered by Cerus.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513776203 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Cerus Corporation
Cerus Corporation developed INTERCEPT technology to improve the safety of donor blood by inactivating pathogens (viruses and bacteria). This chart shows how investors estimate its revenue, which depends on the adoption of its technology in blood banks worldwide—a slow process but with enormous potential for healthcare.
P/S market segment - Medical instruments
Cerus Corporation is a biomedical company specializing in blood safety technologies. Its INTERCEPT system is used to inactivate pathogens (viruses, bacteria) in donor platelets and plasma, reducing the risk of infection during transfusions. This chart shows the average rating in the sector, helping to understand how the market values this critical technology.
P/S of the market as a whole
Cerus Corporation developed the INTERCEPT system to improve the safety of donor blood. The technology inactivates pathogens (viruses and bacteria) in blood components, reducing the risk of transfusion-related infections. This market valuation chart compares how investors value revenue in the unique and vital blood safety niche.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Cerus Corporation
Cerus Corporation supplies systems to improve the safety of donor blood. Future revenue depends on the implementation of its technology in blood banks worldwide. This chart shows how investors view the growing demand for safer blood components and Cerus's market share.
%20P%2FS%20Cerus%20Corporation&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Cerus-Corporation&v=1772513776284 "The graph of the company's future (projected) P/S Cerus Corporation")
Future (projected) P/S of the market segment - Medical instruments
Cerus Corporation developed INTERCEPT technology to improve donor blood safety by inactivating pathogens. This chart compares the company's estimated future sales with those of other medical device manufacturers. It shows how investors view the adoption of its technology in blood banks worldwide to reduce the risk of infection.
%20P%2FS%20market%20segment%20graph%20-%20Medical%20instruments&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Medical-instruments&v=1772513776292 "Future (projected) P/S market segment graph - Medical instruments")
Future (projected) P/S of the market as a whole
Cerus Corporation has developed a technology for inactivating pathogens in blood components, improving transfusion safety. Demand for its system depends on healthcare standards. General economic optimism, reflected in this graph, influences healthcare system budgets and their willingness to implement new technologies to improve patient safety.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513776309 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Cerus Corporation
Cerus Corporation developed INTERCEPT technology to improve donor blood safety by inactivating pathogens. The company's revenue comes from sales of single-use kits for processing blood components (platelets and plasma). The chart shows the growing adoption of its technology by blood banks worldwide to protect recipients.
Sales of companies in the market segment - Medical instruments
Cerus Corporation specializes in blood safety technologies. Its Intercept system is designed to inactivate pathogens (viruses, bacteria) in donor blood and platelets. The company generates revenue from the sale of single-use kits for this system. This chart illustrates the growing demand for improved blood transfusion safety worldwide, where Cerus is the industry standard.
Overall market sales
Cerus Corporation supplies technologies to improve the safety of donor blood. Demand for its systems is driven by healthcare safety standards and is stable. However, expansion into new markets and the introduction of new products depend on blood bank budgets, which are indirectly affected by the overall economic situation, as reflected in the graph.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Cerus Corporation
Cerus Corporation has developed the INTERCEPT system for inactivating pathogens (viruses and bacteria) in blood components such as platelets and plasma, improving transfusion safety. This chart shows analysts' expectations for the adoption of this technology in blood banks worldwide, which is a key growth driver for Cerus.
%20sales%20of%20the%20company%20Cerus%20Corporation&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Cerus-Corporation&v=1772513776379 "Schedule of future (projected) sales of the company Cerus Corporation")
Future (projected) sales of companies in the market segment - Medical instruments
Cerus Corporation developed INTERCEPT technology to improve blood transfusion safety by inactivating pathogens. This graph illustrates expectations for the medical instruments sector. It helps analyze how the implementation of blood safety standards worldwide is creating growing and stable demand for the company's products.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Medical%20instruments&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Medical-instruments&v=1772513776392 "Schedule of future (projected) sales of companies in the market segment - Medical instruments")
Future (projected) sales of the market as a whole
Cerus Corporation supplies systems for the inactivation of pathogens in blood components, improving transfusion safety. This schedule, reflecting healthcare costs, is important to the company. Economic stability allows blood centers and hospitals to implement advanced safety technologies, supporting demand for Cerus' INTERCEPT systems.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513776398 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Cerus Corporation
Cerus Corporation is a leader in blood safety. The company produces the INTERCEPT system, which inactivates pathogens in donor blood and platelets. This chart shows how the company is turning its vital technology into a commercial success, expanding its adoption in blood banks worldwide and ensuring profitability.
Market segment marginality - Medical instruments
Cerus Corporation developed the INTERCEPT system to improve blood donation safety. The technology inactivates pathogens (viruses and bacteria) in blood components before transfusion. This graph shows how their unique and critical healthcare technology is translating into operational efficiencies as it is implemented globally.
Market marginality as a whole
Cerus Corporation developed INTERCEPT technology to improve donor blood safety by inactivating pathogens. Their overall profitability is driven by the trend toward higher blood safety standards. Their profitability depends on the adoption of their technology by blood centers worldwide, a long but steady process.
Employees in the company, segment and market as a whole
Number of employees in the company Cerus Corporation
Cerus Corporation is a leader in blood safety, having developed the INTERCEPT pathogen inactivation system. This chart shows the team working on the global implementation of this technology. The growth in staff reflects the expanding use of its products by blood banks and hospitals worldwide.
Share of the company's employees Cerus Corporation within the market segment - Medical instruments
Cerus Corporation is a leader in blood safety, offering the INTERCEPT system for inactivating pathogens in blood components. This chart shows the company's market share in this important niche. It reflects the scale of its team, which helps make donated blood and platelets safer for transfusion to patients worldwide.
Number of employees in the market segment - Medical instruments
Cerus Corporation developed the INTERCEPT system to improve donor blood safety by inactivating pathogens. This chart shows employment in the medical technology sector. The steady growth in employment reflects the gradual adoption of this important technology in blood banks worldwide to reduce the risk of transfusion-related infections.
Number of employees in the market as a whole
Cerus Corporation developed INTERCEPT technology to improve the safety of donated blood. The system inactivates pathogens in blood components, reducing the risk of transfusion-related infections. This graph illustrates overall employment, and companies like Cerus make a critical contribution to the healthcare system by creating jobs in biotechnology and medical manufacturing.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Cerus Corporation (CERS)
Cerus Corporation develops technologies to improve blood donation safety. It's a healthcare business dominated by intellectual property. This chart shows a high market capitalization per employee. The market values their patented INTERCEPT technology, which has become an industry standard. A small team can support a product with global reach.
%20of%20the%20company%20Cerus%20Corporation%20(CERS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Cerus-Corporation-CERS&v=1772513776633 "Chart of market capitalization per employee (in thousands of dollars) of the company Cerus Corporation (CERS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Medical instruments
908 Devices produces compact mass spectrometers for rapid, on-site chemical analysis. This is a breakthrough technology for many industries. The chart shows how the market perceives the potential for miniaturization of complex instruments. The high cost per employee reflects investors' belief that a small team of engineers can transform an entire industry.
%20by%20market%20segment%20-%20Medical%20instruments&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Medical-instruments&v=1772513776655 "Market capitalization per employee (in thousands of dollars) by market segment - Medical instruments")
Market capitalization per employee (in thousands of dollars) for the overall market
Cerus Corporation developed INTERCEPT technology to improve the safety of donor blood by inactivating pathogens. This is a critical product for blood banks. This chart reflects how the market values this unique technology. The cost per employee reflects the critical role they play in ensuring blood transfusion safety.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513776685 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Cerus Corporation (CERS)
Cerus (CERS) produces the INTERCEPT system for purifying (deactivating pathogens) donor blood and platelets. This is a critical product for blood safety. This chart shows how successfully the company is monetizing this technology. It measures how much revenue each employee generates by selling consumables for this system to blood banks.
%20Chart%20Cerus%20Corporation%20(CERS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Cerus-Corporation-CERS&v=1772513776813 "Company Profit Per Employee (in thousands of dollars) Chart Cerus Corporation (CERS)")
Profit per employee (in thousands of dollars) in the market segment - Medical instruments
Cerus Corporation is focused on blood safety. Their INTERCEPT system is a technology that purifies donated blood of viruses and bacteria. Their business is consumables. This chart shows an industry benchmark. It helps evaluate how effectively the Cerus team is monetizing their vital and patented technology.
%20in%20the%20market%20segment%20-%20Medical%20instruments&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Medical-instruments&v=1772513776835 "Chart of profit per employee (in thousands of dollars) in the market segment - Medical instruments")
Profit per employee (in thousands of dollars) for the market as a whole
Cerus Corporation is known for its INTERCEPT system for purifying (inactivating pathogens) donor blood and platelets. It's a "razor and blade" model. They sell the equipment (the "razor") and, more importantly, disposable kits for each procedure (the "blades"). This graph shows how effectively their team is growing their installed base, leading to higher-margin revenue from consumables.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513776884 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Cerus Corporation (CERS)
Cerus Corporation developed the INTERCEPT system to improve blood donation safety. This chart shows the commercialization of this unique medical technology. The growth in revenue per employee reflects the growing adoption of their system in blood centers worldwide, enabling revenue generation from the sale of consumables for each procedure.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Cerus-Corporation-CERS&v=1772513776911 "Sales chart per company employee Cerus Corporation (CERS)")
Sales per employee in the market segment - Medical instruments
Cerus (CERS) is the company that developed the INTERCEPT system for inactivating pathogens (viruses, bacteria) in blood components (platelets, plasma). This graph shows the revenue (from sales of systems and consumables) generated by each employee. It is an indicator of the commercial success of their technology, which improves the safety of blood transfusions.
Sales per employee for the market as a whole
Cerus Corporation (CERS) is the company behind the INTERCEPT system, which is used to inactivate pathogens (viruses and bacteria) in donated blood. It's a "razor and blade" business (the system and disposable kits). This chart shows how successfully the company generates revenue from selling these vital consumables to blood centers worldwide.
Short shares by company, segment and market as a whole
Shares shorted by company Cerus Corporation (CERS)
Cerus Corporation is a company that produces the Intersect system for inactivating pathogens in donor blood and platelets. This chart shows bearish bets. Shorts may be driven by slow adoption of their technology in blood banks (due to high costs) or regulatory hurdles in new regions.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Cerus-Corporation-CERS&v=1772513776995 "Short Shares Chart for the Company Cerus Corporation (CERS)")
Shares shorted by market segment - Medical instruments
Cerus (CERS) is a company that produces the INTERCEPT system, which is used to inactivate pathogens (viruses, bacteria) in donor blood and platelets. This chart shows bets against the MedTech sector. The rising bets against the industry may reflect investor concerns about the slow adoption of this technology by blood banks or competition.
Shares shorted by the overall market
Cerus Corporation (CERS) supplies blood safety technologies (pathogen inactivation). It's a niche medical business with stable demand. This market fear chart shows investors seeking protection. CERS's products are critical for blood banks, so the company's business is considered defensive.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Cerus Corporation (CERS)
Cerus Corporation produces pathogen inactivation systems for blood components. Its business depends on blood bank adoption. A chart above 70 may reflect increased adoption or large contracts. A chart below 30 may indicate slow adoption or regulatory issues.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Cerus-Corporation-CERS&v=1772513777087 "RSI 14 indicator chart for the company's stock Cerus Corporation (CERS)")
RSI 14 Market Segment - Medical instruments
Cerus Corporation is a leader in blood safety. Its INTERCEPT system is used to inactivate pathogens in donor platelets and plasma, saving lives. This business relies on implementation in blood banks. This chart tracks the collective sentiment in the medical device sector. It helps understand whether CERS's fluctuations are driven by its unique technology or a general "wave" in medical technology.
RSI 14 for the overall market
Cerus (CERS) produces blood safety systems (pathogen purification). This chart shows that its business is "defensive." Demand for blood safety isn't driven by euphoria or panic—it's driven by medical standards. During times of market panic, investors seek safe havens in companies with non-cyclical demand.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CERS (Cerus Corporation)
Cerus Corporation is a leader in blood safety. Its INTERCEPT system inactivates pathogens (viruses, bacteria) in platelets and plasma. This chart shows the average analyst forecast. Their targets are based on growing sales of INTERCEPT system consumables to blood centers worldwide.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CERS-Cerus-Corporation&v=1772513777128 "A chart showing analyst consensus forecasts for the expected stock price. CERS (Cerus Corporation)")
The difference between the consensus estimate and the actual stock price CERS (Cerus Corporation)
Cerus (CERS) is a company that dominates the pathogen inactivation (INTERCEPT) market. Their system purifies donor blood (platelets, plasma) of viruses and bacteria. This chart shows their market cap estimate. It measures the gap between the price and the consensus target, reflecting whether analysts believe their technology will become the de facto standard.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CERS-Cerus-Corporation&v=1772513777149 "A chart showing the difference between the consensus forecast and the actual stock price. CERS (Cerus Corporation)")
Analyst consensus forecast for stock prices by market segment - Medical instruments
Cerus Corporation (CERS) dominates the pathogen inactivation market. Its Intercept system purifies donor blood components (platelets, plasma) from viruses and bacteria. This chart shows general expectations for the medical devices sector. It reflects whether experts believe blood safety standards will improve.
Analysts' consensus forecast for the overall market share price
Cerus Corporation is a company specializing in blood safety. Their system (Intercept) is used to inactivate pathogens (viruses, bacteria) in donor blood and platelets. This chart shows the overall market sentiment. For Cerus, which operates in the protective healthcare sector, the overall optimism is important, but their demand is primarily driven by blood safety standards.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Cerus Corporation
Cerus (CERS) is a blood custodian. Their INTERCEPT system is the world's only FDA-approved product for pathogen inactivation of donor blood (platelets, plasma), killing viruses and bacteria. This chart is a summary indicator of their razor and blade products. It reflects their ability to sell razors (devices) and their growing, high-margin blade revenue for each blood pack.
AKIMA Market Segment Index - Medical instruments
Cerus Corporation is a leader in blood safety. Their INTERCEPT system inactivates pathogens in blood components (platelets, plasma). This chart shows the average index for the medical instruments sector. It allows one to assess how Cerus' technology, which has become a standard in many countries, helps the company outperform the industry average.
The AKIM Index for the overall market
Cerus Corporation is a biomedical company that developed the INTERCEPT system for inactivating pathogens in blood components (plasma, platelets). This chart, which reflects the market average, is a backdrop. It helps assess how this blood transfusion safety standard compares to general macroeconomic fluctuations in healthcare.
